SA EMS ROAD EXPERIENCE • HPCSA STATUTORY DRUG MONOGRAPH
TRANEXAMIC ACID (TXA)
Tranexamic Acid (Brand Names: Cyklokapron, Transamin, Lysteda)
HPCSA CDST 2024 (Version 1.3 Framework)
Official Statutory Clinical Reference
Antifibrinolytic • Synthetic Lysine Analogue • Hemostatic AgentHPCSA CDST 2024 (v1.3 Framework)
•
TRANEXAMIC ACID (TXA)
Tranexamic Acid (Brand Names: Cyklokapron, Transamin, Lysteda)
Clinical Summary: A synthetic lysine analogue antifibrinolytic that competitively blocks plasminogen activation to preserve forming blood clots, preventing catastrophic exsanguination in severe polytrauma and postpartum hemorrhage.
Authorized HPCSA Emergency Care Scope of Practice (Annexure A 2022)Statutory Board Mandate
LEGENDARY CCA (^) [ANT PARAMEDIC]NDIP EMC (^) [ANT PARAMEDIC]ECP ONLY (~)
TRANEXAMIC ACID (TXA) Audio BriefingCLINICAL PROFESSOR
No Audio Published Yet
00:00Full Monograph
1. Mechanism of Action
How this drug operates physiologically in the human body
2. Statutory Clinical Indications
2 UsesStrictly per HPCSA CDST v1.3, Annexure A & CPG
3. Adverse Effects & Pathophysiology
Why the body reacts and why it occurs in specific indications
4. Contraindications & Lethal Risks
Biological consequences & why it threatens life
5. Statutory Resources & Quotes
Verbatim regulatory excerpts with deep external links
SA EMS FIELD PROTOCOLS • EDUCATIONAL REVIEW & STATUTORY CITATIONS
An independent educational review and study companion based on the official HPCSA CDST 2024 (Version 1.3 Framework), CPG 2018, and Annexure A (2022) sourced directly from the official HPCSA publication portal. Not for live on-scene patient management.
Author: Jacoline (Jax) Geldenhuys, BEMC • HPCSA Registered Emergency Care Practitioner (ECP)